SNY Sanofi American Depositary Shar

-0.03  -0%
Previous Close 49.03
Open 48.98
Price To book 1.99
Market Cap 123.75B
Shares 2,525,475,000
Volume 1,071,057
Short Ratio 3.17
Av. Daily Volume 1,730,420

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial to be initiated 3Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
Phase 3 trial initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
Phase 3 trial to commence 4Q 2017.
Type 2 diabetes
Phase 3 program to be initiated 3Q 2017.
Fitusiran (ATLAS)
Phase 3 top-line data due mid-2017.
Patisiran APOLLO
Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR
Phase 3 data due 1Q 2018.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 trial initiated 4Q 2016.
Type 2 Diabetes
Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial due mid-2017.
Type 1 Diabetes
Phase 3 enrollment commenced November 2016.
Pompe disease
Phase 3 trial initiated December 2017.
Refractory Multiple Myeloma
Phase 3 data due 4Q 2017.
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Phase 3 enrollment commenced 2Q 2017.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 trial commenced 4Q 2017.
Dupixent (dupilumab)
Nasal polyps
Pivotal Phase 2/3 trial ongoing.
Cutaneous squamous cell carcinoma
Pivotal Phase 2/3 trial started in July 2016
Olipudase alfa
Acid sphingomyelinase deficiency (ASMD)
Phase 2 trial to commence 1H 2017.
Non-small cell lung cancer (NSCLC)
Phase 2 trial to commence 1H 2017.
Basal cell carcinoma
Phase 2 trial to commence in 2017.
Dupixent (dupilumab)
Food Allergy
Phase 2 data released May 4, 2017.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Rheumatoid arthritis

Latest News

  1. Are Regeneron, Sanofi Treading On Pfizer In Eczema?
  2. 3 Top Dividend Stocks in Generic Drugs
  3. Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports
  4. Performance of Sanofi Genzyme in 1Q17
  5. Sanofi’s Revenue Growth in 1Q17
  6. Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
  7. Changes in Sanofi’s Valuation after Its 1Q17 Earnings
  8. Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks
  9. Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline
  10. Gardasil and Merck’s Vaccines Business in 1Q17
  11. Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis
  12. ​Sanofi Genzyme takes on world’s top-selling drugs with new approval
  13. Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
  14. Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval
  15. Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
  16. Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients
  17. Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
  18. Regeneron And Sanofi Have A Near-Term FDA Catalyst
  19. Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?
  20. Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of Diabetes Mellitus